Abstract：Objective To investigate the clinical effect of Albumin-bound Paclitaxel combined with Tegafur Gimeracil Oteracil Potassium in the treatment of elderly advanced pancreatic cancer.Methods A total of 50 elderly patients with advanced pancreatic cancer admitted to the Fifth People′s Hospital of Dalian from January 2018 to January 2020 were selected as the research subjects.By the random number table method,they were divided into test group (n=25) and control group (n=25).Patients in the test group were treated with Albumin-bound Paclitaxel combined with Tegafur Gimeracil Oteracil Potassium,and in the control group,Gemcitabine was used.The clinical efficacy,overall survival,median survival and 6-month survival rate of the two groups were compared.The adverse reactions of the two groups were also compared.Results The disease control rate and 6-month survival rate of the test group were higher than those of the control group,the overall survival and median survival were longer than those of the control group,with statistically significant differences (P<0.05).There was no statistical difference in the effectiveness rate between the two groups (P>0.05).The incidence rates of adverse reactions such as leukopenia,thrombocytopenia and nausea and vomiting in the test group were lower than those in the control group,and the differences were statistically significant (P<0.05).Conclusion For elderly patients with advanced pancreatic cancer,the combination of Albumin-bound Paclitaxel and Tegafur Gimeracil Oteracil Potassium has good efficacy and safety for them.
Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].C A Cancer J Clin，2018，68（6）：394-424.
[2]
Siegel RL，Miller KD，Jemal A.Cancer statistics，2019[J].C A Cancer J Clin，2019，69（1）：7-34.
Kamarajah SK，Burns WR，Frankel TL，et al.Validation of the American Joint Commission on Cancer （AJCC） 8thedition staging system for patients with pancreatic adenocarcinoma：a Surveillance，Epidemiology and End Results（SEER）analysis[J].Ann Surg Oncol，2017，24（7）：2023-2030.
Valsecchi ME，Diaz-Canton E，De La Vega M，et al.Recent treatment advances and novel therapies in pancreas cancer：a review[J].J Gastrointest Cancer，2014，45（2）：190-201.
[10]
Wickremsinhe E，Bao J，Smith R，et al.Preclinical absorption，distribution，metabolism，and excretion of an oral amide prodrug of gemicitabine designed to deliver prolonged systemic exposure[J].Pharmaceutics，2013，5（2）：261-276.
Neuzillet C，Tijeras-Raballand A，Cros J，et al.Stromal expression of SPARC in pancreatic adenocarcinoma [J].Cancer Metastasis Rev，2013，32（3-4）：585-602.
[14]
Hoy SM.Albumin-bound paclitaxel：a review of its use for the firstline combination treatment of metastatic pancreatic cancer[J].Drugs，2014，74（15）：1757-1768.
[17]
Imaoka H，Kou T，Tanaka M，et al.Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1，S-1 alone，or gemcitabine alone：Subgroup analysis of a randomised phase Ⅲtrial，GEST study[J].Eur J Cancer，2016，54：96-103.
京公网安备 11010502046607号